Skip to main content
Erschienen in: Psychiatric Quarterly 4/2017

01.02.2017 | Original Paper

Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment

verfasst von: Kun-Po Chen, For-Wey Lung

Erschienen in: Psychiatric Quarterly | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to develop a reliable and valid short version of the Udvalg for Kliniske Undersogelser (UKU) to efficiently evaluate the side effects of antipsychotics in patients with schizophrenia. This multi-site study included 10 hospitals, which included 331 inpatients and outpatients diagnosed with schizophrenia. UKU, Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP) and dosage of paliperidone were collected. The predictive validity of the UKU-short version, as well as that of the CGI-S, PSP and paliperidone dosages, was analyzed using structural equation modeling (SEM), latent growth models (LGM), and confirmatory factor analysis to test its content and construct validity. The UKU-short included nine-items of sedation, reduced sleep, rigidity, tremor, akathisia, headache, reduced salivation, constipation and orthostatic dizziness, and has good construct and content validity over time. Confirmatory factor analysis showed good construct validity, with the psychic, neurological and autonomic side effect dimensions having correlations between 0.60 and 0.71. The predictive validity of the short-version UKU for psychiatric symptoms (CGI-S), quality of life (PSP) and dosage showed that the effects of drug dosage were negligible, and only neurological side effects were associated with psychiatric symptoms and quality of life. The UKU-short showed good content, construct and predictive validity. It is a more time-efficient instrument than the original UKU. This study only included patients treated with paliperidone, larger scale studies is needed to validate the UKU-short in detection of side effects in routine clinical practice to prevent non-adherence in patients with schizophrenia.
Literatur
1.
Zurück zum Zitat Donohoe G, Owens N, O'Donnell C et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16:293-8.CrossRefPubMed Donohoe G, Owens N, O'Donnell C et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16:293-8.CrossRefPubMed
2.
Zurück zum Zitat Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54:665-777.CrossRefPubMed Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54:665-777.CrossRefPubMed
3.
Zurück zum Zitat Velligan DI, Weiden PJ, Sajatovic M et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1-46.PubMed Velligan DI, Weiden PJ, Sajatovic M et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1-46.PubMed
4.
Zurück zum Zitat Kane JM. Dosage and route of administration of neuroleptic drugs during different phases of schizophrenia illness. In: Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer; 1994. Kane JM. Dosage and route of administration of neuroleptic drugs during different phases of schizophrenia illness. In: Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer; 1994.
5.
Zurück zum Zitat Lader M, Lewander T. The neuroleptic-induced deficit syndrome. Acta Psychiatr Scand. 1994;89 (Suppl 380):1-85 Lader M, Lewander T. The neuroleptic-induced deficit syndrome. Acta Psychiatr Scand. 1994;89 (Suppl 380):1-85
6.
Zurück zum Zitat Day JC, Wood G, Dewy M, Bentall RP. A self-rating scale for measuring neuroleptic side effects: Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-3CrossRefPubMed Day JC, Wood G, Dewy M, Bentall RP. A self-rating scale for measuring neuroleptic side effects: Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-3CrossRefPubMed
7.
Zurück zum Zitat Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71CrossRefPubMed Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71CrossRefPubMed
8.
Zurück zum Zitat Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27.CrossRefPubMed Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27.CrossRefPubMed
9.
Zurück zum Zitat Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 2000;148:3-15.CrossRefPubMed Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 2000;148:3-15.CrossRefPubMed
10.
Zurück zum Zitat Piparva KG, Buch JG, Chandrani KV. Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD. Indian J Psychol Med. 2011;33:153-7.CrossRefPubMedPubMedCentral Piparva KG, Buch JG, Chandrani KV. Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD. Indian J Psychol Med. 2011;33:153-7.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs 2012;26:601-11.CrossRefPubMed Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs 2012;26:601-11.CrossRefPubMed
12.
Zurück zum Zitat Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012;43:906-13.CrossRefPubMed Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012;43:906-13.CrossRefPubMed
13.
Zurück zum Zitat Rosen JB, Milstein MJ, Haut SR. Olanzapine-associated myoclonus. Epilepsy Res. 2012;98:247-50.CrossRefPubMed Rosen JB, Milstein MJ, Haut SR. Olanzapine-associated myoclonus. Epilepsy Res. 2012;98:247-50.CrossRefPubMed
14.
Zurück zum Zitat Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Legen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scand. 1987;76:1-100.CrossRef Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Legen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scand. 1987;76:1-100.CrossRef
15.
Zurück zum Zitat Lambert TJR, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol Clin Exp. 2003;18:405-11.CrossRef Lambert TJR, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol Clin Exp. 2003;18:405-11.CrossRef
16.
Zurück zum Zitat Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine with coadministered with haloperidol, risperidone, or thioridazine. J Psychopharmacol. 2002;22:121-30.CrossRef Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine with coadministered with haloperidol, risperidone, or thioridazine. J Psychopharmacol. 2002;22:121-30.CrossRef
17.
Zurück zum Zitat Chen YL, Cheng TS, Lung FW. Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry 2009;11:16-20.CrossRefPubMedPubMedCentral Chen YL, Cheng TS, Lung FW. Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry 2009;11:16-20.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand. 1994;89:11-5. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand. 1994;89:11-5.
19.
Zurück zum Zitat Wang CS, Kao WT, Chen CD, Tung YP, Lung FW. Priapism associated with typical and atypical antipsychotic medications. Int Clin Psychopharmacol. 2006;21:245-8.CrossRefPubMed Wang CS, Kao WT, Chen CD, Tung YP, Lung FW. Priapism associated with typical and atypical antipsychotic medications. Int Clin Psychopharmacol. 2006;21:245-8.CrossRefPubMed
20.
Zurück zum Zitat Lee HH, Chu YH, Ruan FF, Tzeng DS, Lung FW. Confirmatory factor analysis of the Sexual Desire Inventory for schizophrenia patients. Taiwanese Journal of Psychiatry 2007;21:176-83. Lee HH, Chu YH, Ruan FF, Tzeng DS, Lung FW. Confirmatory factor analysis of the Sexual Desire Inventory for schizophrenia patients. Taiwanese Journal of Psychiatry 2007;21:176-83.
21.
Zurück zum Zitat Lee HH, Lung FW, Lee PR, Kao WT, Lee YL. The relationship between sex life satisfaction and job stress of married nurses. BMC Res Notes 2012;5:445.CrossRefPubMedPubMedCentral Lee HH, Lung FW, Lee PR, Kao WT, Lee YL. The relationship between sex life satisfaction and job stress of married nurses. BMC Res Notes 2012;5:445.CrossRefPubMedPubMedCentral
22.
23.
Zurück zum Zitat Ong J, Wong W, Lee A, Holroyd E, Huang SY. Sexual activity and adolescent health risk behaviours amongst high school students in three ethnic Chinese urban populations. J Clin Nurs. 2013;22:3270-9.CrossRefPubMed Ong J, Wong W, Lee A, Holroyd E, Huang SY. Sexual activity and adolescent health risk behaviours amongst high school students in three ethnic Chinese urban populations. J Clin Nurs. 2013;22:3270-9.CrossRefPubMed
24.
Zurück zum Zitat Tsai JK, Lin WK, Lung FW. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343-51.CrossRefPubMed Tsai JK, Lin WK, Lung FW. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343-51.CrossRefPubMed
25.
Zurück zum Zitat Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm). Bethesda MD: National Institute of Mental Health; 1976. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm). Bethesda MD: National Institute of Mental Health; 1976.
26.
Zurück zum Zitat Brissos S, Molodynski A, Dias VV, Figueira ML. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry 2011;10:18.CrossRefPubMedPubMedCentral Brissos S, Molodynski A, Dias VV, Figueira ML. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry 2011;10:18.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Anastasi A, Urbina S. Psychological testing, 7th ed. New York: Prentice Hall; 1997. Anastasi A, Urbina S. Psychological testing, 7th ed. New York: Prentice Hall; 1997.
28.
Zurück zum Zitat Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6:21-6.CrossRefPubMed Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6:21-6.CrossRefPubMed
29.
Zurück zum Zitat Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS ONE 2012;7:e37087.CrossRefPubMedPubMedCentral Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS ONE 2012;7:e37087.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Ghisletta P, Lindenberger U. Static and dynamic longitudinal structural analyses of cognitive changes in old age. Gerontology 2004;50:12-6.CrossRefPubMed Ghisletta P, Lindenberger U. Static and dynamic longitudinal structural analyses of cognitive changes in old age. Gerontology 2004;50:12-6.CrossRefPubMed
32.
Zurück zum Zitat Chugh PK, Rehan HS, Unni KES, Sah RK. Predictive value of symptoms for quality of life in first-episode schizophrenia. Nord J Psychiatry 2013;67:153-8.CrossRefPubMed Chugh PK, Rehan HS, Unni KES, Sah RK. Predictive value of symptoms for quality of life in first-episode schizophrenia. Nord J Psychiatry 2013;67:153-8.CrossRefPubMed
33.
Zurück zum Zitat Yang MC, Lung FW. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology 2011;217:397–410.CrossRefPubMed Yang MC, Lung FW. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology 2011;217:397–410.CrossRefPubMed
Metadaten
Titel
Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment
verfasst von
Kun-Po Chen
For-Wey Lung
Publikationsdatum
01.02.2017
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 4/2017
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-017-9494-y

Weitere Artikel der Ausgabe 4/2017

Psychiatric Quarterly 4/2017 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.